Health Condition 1: J00- Acute nasopharyngitis [common cold]
Conditions
Interventions
Intervention1: SACHET SACCROMYCES BOULLARDII CNCMI 745: 1.Study group will be provided with 10 sachets each containing Sacchromyces Boulardii CNCM I 745 strain 250 mg after explaining the aims and obj
Sponsors
Dr Rachita Sewara
Eligibility
Inclusion criteria
Inclusion criteria: The present Double-blind, randomised, placebo-controlled clinical trial will be carried out after approval by the ethics committee of Dr. S. N. Medical College, Jodhpur and subjects will enrolled after written informed consent. Children attending Paediatric clinic of or are admitted in the paediatrics wards of UMAID /MDM hospital Jodhpur (Rajasthan) and who are prescribed Antibiotics for respiratory illness and otitis media will be recruited for the current study.
Exclusion criteria
Exclusion criteria: children having any clinical evidence of: 1. Known chronic or recurrent systemic disorder associated with immunocompromised. 2. A history of allergy or hypersensitivity to Saccharomyces boulardii, brewer’s or baker’s yeast, Amoxicillin-Clavulanate, amoxicillin or other penicillins, or cephalosporins. 3. Prior gastrointestinal surgery. 4. Known and diagnosed cases of Celiac disease. 5. Diagnosed case of Cystic fibrosis. 6. Structural GI diseases include strictures, stenosis, hemorrhoids, diverticular disease, colon polyps, colon cancer and inflammatory bowel disease. 7. Oral or systemic antibacterial therapy during the 3 months prior to study enrolment. 8. Prescription, over-the-counter medications or supplements that are known to alter gut function or microflora (i.e., acid anti-secretory drugs, probiotics) during the 4 weeks prior to study enrolment. 9. Chronic or persistent diarrhoea (12 weeks) or severe diarrhoea, i.e. diarrhoea managed with intravenous fluids or requiring hospital admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| we will compared outcomes in both placebo and control groups (S. boulardii vs. placebo) on 6th day by assessing stool ph microscopy and bacterial loadTimepoint: on 6 day | — |
Secondary
| Measure | Time frame |
|---|---|
| Saccromyces boullardii CNCM I 745 play a role in prevention of antibiotic associated gut dysbiosisTimepoint: 6 DAYS | — |
Countries
India
Contacts
Public ContactDr Anurag Singh
DR S.N. Medical College Jodhpur
Outcome results
None listed